Journal of Cardiovascular Pharmacology and Therapeutics最新文献_第3页

Impact of Intravenous Nitrate Treatment on Antiplatelet Effects of Clopidogrel in Acute Coronary Syndrome Patients: A Pilot Study. 静脉硝酸盐治疗对急性冠脉综合征患者氯吡格雷抗血小板作用的影响：一项初步研究。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-07-02 DOI: 10.1177/10742484251357147

Mehmet Melek, Hasan Ari, Alper Karakuş, Selma Ari, Ahmet Tütüncü, Tahsin Bozat

{"title":"Impact of Intravenous Nitrate Treatment on Antiplatelet Effects of Clopidogrel in Acute Coronary Syndrome Patients: A Pilot Study.","authors":"Mehmet Melek, Hasan Ari, Alper Karakuş, Selma Ari, Ahmet Tütüncü, Tahsin Bozat","doi":"10.1177/10742484251357147","DOIUrl":"10.1177/10742484251357147","url":null,"abstract":"BackgroundClopidogrel is a pro-drug that requires metabolic activation by hepatic cytochrome P450 (CYP) enzymes in two steps. Previous studies have shown that the administration of continuous nitrate significantly affects the activity of hepatic CYP. In this pilot study, we assess the impact of intravenous nitrate treatment on the antiplatelet effects of clopidogrel in patients with non-ST-elevation myocardial infarction (NSTEMI).MethodWe included 20 NSTEMI patients: 15 in the nitrate group and five in the control group. All patients received a 300 mg acetylsalicylic acid and a 600 mg clopidogrel loading dose. The nitrate group was administered an intravenous glyceryl trinitrate infusion at 10 µg/min for 48 h. After the drugs were initiated, blood samples were collected from patients at intervals of 30th minutes, 60th minutes, 120th minutes, fourth hour, sixth hour, and 48th hour to assess platelet function. The antiplatelet effect of clopidogrel was evaluated using the platelet reactivity unit (PRU) from the Verify-Now P2Y12 assay.ResultThe PRU values at baseline and the 30th, 60th, 120th minutes, and 48th hour were similar between the two groups (P > .05). However, PRU values at the fourth and sixth hours were significantly higher in the nitrate group than in the control group (274.1 ± 53.9 vs 162.4 ± 39.9; P = .002 and 272.0 ± 67.0 vs 185.6 ± 18.1; P = .03, respectively).ConclusionIntravenous nitrate therapy in patients with NSTEMI delayed the onset of the antiplatelet effect of orally loaded clopidogrel by at least 4 h. This point should be kept in mind in patients using clopidogrel and nitrate therapy together. (NCT06878638).","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251357147"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Efficacy of Canrenone in Restoring Sinus Rhythm in Patients With Atrial Fibrillation-A Pilot, Randomized, Double-Blind Study. 佳能酮恢复心房颤动患者窦性心律的临床疗效——一项先导、随机、双盲研究。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-07-29 DOI: 10.1177/10742484251356361

Rafał Dąbrowski, Agnieszka Segiet-Święcicka, Stefan Sawicki, Ilona Kowalik, Krzysztof Jaworski, Michał Farkowski, Agata Kubaszek-Kornatowska, Piotr Michałek, Mirosław Dłużniewski, Hanna Szwed, Tomasz Hryniewiecki, Jarosław Karwowski

{"title":"Clinical Efficacy of Canrenone in Restoring Sinus Rhythm in Patients With Atrial Fibrillation-A Pilot, Randomized, Double-Blind Study.","authors":"Rafał Dąbrowski, Agnieszka Segiet-Święcicka, Stefan Sawicki, Ilona Kowalik, Krzysztof Jaworski, Michał Farkowski, Agata Kubaszek-Kornatowska, Piotr Michałek, Mirosław Dłużniewski, Hanna Szwed, Tomasz Hryniewiecki, Jarosław Karwowski","doi":"10.1177/10742484251356361","DOIUrl":"10.1177/10742484251356361","url":null,"abstract":"Background and aimsRenin-angiotensin-aldosterone system (RAAS) inhibition is an upstream therapy for managing atrial fibrillation (AF). Of all RAAS-inhibiting agents, only canrenone in the form of potassium canrenoate, a specific inhibitor of mineralocorticoid receptors, is administered intravenously. We evaluated the clinical efficacy of intravenous potassium canrenoate in restoring sinus rhythm in patients with paroxysmal AF episodes.MethodsThis double-center, randomized, double-blind study comprised 52 patients with AF (lasting <48 h) in stable cardiopulmonary conditions who were eligible for cardioversion. The patients were randomly assigned to receive a slow intravenous bolus of 10 ml either as a placebo (0.9% saline) or canrenone (200 mg). The primary endpoint was the return of sinus rhythm within 2 h after drug administration.ResultsOf 52 patients, 27 (51.9%) and 25 (48.1%) were treated with placebo and canrenone, respectively. The median patient age was 68 years, and 27 patients (51.9%) were men. Sinus rhythm restoration during the follow-up period occurred in 3 (11.5%) and 4 (16.0%) patients in the placebo and canrenone arms (P = .477), respectively. Adverse events were observed in 2 (7.4%) and 0 (0.0%) patients in the placebo and canrenone arms, respectively (P = .170).ConclusionsIntravenous canrenone is not effective in the sinus rhythm restoration among the patients with paroxysmal AF.ClinicalTrials.gov. NCT03536806.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251356361"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Pathophysiology of Vasovagal Syncope and New Approaches to its Pharmacological Treatment. 血管迷走神经性晕厥的病理生理及药物治疗新途径。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-06-20 DOI: 10.1177/10742484251351140

Dalyia Abu-Ghazaleh, David A Taylor, Louise Roberts, Indu Singh, Vinicius Cruzat, Roselyn B Rose'Meyer

{"title":"The Pathophysiology of Vasovagal Syncope and New Approaches to its Pharmacological Treatment.","authors":"Dalyia Abu-Ghazaleh, David A Taylor, Louise Roberts, Indu Singh, Vinicius Cruzat, Roselyn B Rose'Meyer","doi":"10.1177/10742484251351140","DOIUrl":"10.1177/10742484251351140","url":null,"abstract":"Syncope refers to the transient loss of consciousness and the most common type of syncope is vasovagal syncope (VVS), usually occurring when a person is in an upright position, and/or after exposure to intense stress. The sequelae of VVS is caused by an increase in sympathetic tone and heart rate combined with an underfilled left ventricular chamber that leads to stimulation of cardiac afferent C fibers ultimately leading to bradycardia and vasodilation causing a reduction in venous return, cerebral hypoperfusion and VVS. Several treatment options have been tested including physical counter-pressure measures, electrical pacing, cardioneuroblation. Pharmacological interventions and clinical trials for VVS are summarized in this review; however, there is still limited evidence of their efficacy for reducing episodes of VVS. This review will examine studies using animal models of the vasovagal reflex arc to investigate the physiological mechanisms and neurotransmitters associated with VVS, the tilt-table test that induces VVS in patients and the potential sources of cardiac and platelet mediators that can activate cardiac afferent C fibers. This study will also consider how the previously investigated pharmacotherapies provide insight into the multiple mechanisms involved in VVS and propose new targets for the pharmacological treatment of VVS.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251351140"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LncRNA Sirt1-AS Protects Against Cardiac Hypertrophy by Modulating Sirt1. LncRNA Sirt1- as通过调节Sirt1抑制心肌肥厚。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-08-29 DOI: 10.1177/10742484251356358

Xuejiao Wei, Chenrui Zhang, Shuanglong Mou, Yongqin He, Xiaoyun Si, Bing Li

{"title":"LncRNA Sirt1-AS Protects Against Cardiac Hypertrophy by Modulating Sirt1.","authors":"Xuejiao Wei, Chenrui Zhang, Shuanglong Mou, Yongqin He, Xiaoyun Si, Bing Li","doi":"10.1177/10742484251356358","DOIUrl":"10.1177/10742484251356358","url":null,"abstract":"BackgroundLncRNAs are pivotal regulators in cardiovascular diseases. Sirt1-AS, a lncRNA, has been shown to play a role in cardiovascular diseases. This study aimed to explore the role of Sirt1-AS in cardiac hypertrophy and the underlying molecular mechanism.MethodsA mouse model of pressure-overload cardiac hypertrophy was established via transverse aortic constriction (TAC). Cardiac tissues of TAC mice and cardiomyocytes treated with angiotensin II (AngII) were examined for Sirt1-AS and Sirt1 expression levels. The effects of Sirt1-AS overexpression or knockdown on cardiomyocyte size and hypertrophic marker expression were accessed. Furthermore, the molecular interaction between Sirt1-AS and Sirt1 were investigated.ResultsSirt1-AS expression was found to be downregulated in the hearts of TAC mice and in Ang II-treated cardiomyocytes. Overexpression of Sirt1-AS attenuated cardiac hypertrophy, while its suppression exacerbated the hypertrophic response. Mechanistic studies demonstrated that Sirt1-AS directly influenced Sirt1 mRNA and protein expression levels. Moreover, the protective effects of Sirt1-AS against cardiac hypertrophy were abolished upon Sirt1 mRNA inhibition.ConclusionOur findings suggest that Sirt1-AS exerts a protective effect against cardiac hypertrophy by modulating Sirt1 expression. This research provides novel insights into the role of lncRNAs in cardiac hypertrophy and highlights Sirt1-AS as a potential therapeutic target for the treatment of cardiac hypertrophy.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251356358"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Concomitant Therapy of Direct Oral Anticoagulants with Amiodarone in Atrial Fibrillation: A Meta-analysis. 直接口服抗凝剂与胺碘酮联合治疗心房颤动：荟萃分析。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-06-20 DOI: 10.1177/10742484251351148

Kazuhiko Kido, Mikiko Shimizu, Tsuyoshi Shiga, Masayuki Hashiguchi

{"title":"The Concomitant Therapy of Direct Oral Anticoagulants with Amiodarone in Atrial Fibrillation: A Meta-analysis.","authors":"Kazuhiko Kido, Mikiko Shimizu, Tsuyoshi Shiga, Masayuki Hashiguchi","doi":"10.1177/10742484251351148","DOIUrl":"10.1177/10742484251351148","url":null,"abstract":"BackgroundThe concomitant therapy of amiodarone with direct oral anticoagulants (DOACs) significantly increases the concentrations of DOACs and may increase the bleeding risks. Multiple real-world studies compared the concomitant therapy of amiodarone and DOACs versus the DOAC alone, but their main findings were contradictory.MethodsA meta-analysis compared the concomitant therapy of amiodarone and DOACs versus DOACs monotherapy. Database searches through May 1, 2025, were performed. The primary outcome was major bleeding. The secondary outcomes included stroke or systemic embolism, any bleeding, all-cause mortality, gastrointestinal bleeding, and intracranial bleeding.ResultsThis meta-analysis included a total of nine studies. There were no significant differences in major bleeding between the concomitant therapy of amiodarone and DOAC and DOAC monotherapy groups (OR 1.12; 95% CI 0.98, 1.27; P = .09; I2 = 64%). No significant differences in any bleeding (OR 1.18; 95% CI 0.88, 1.57; P = .27; I2 = 77%), gastrointestinal bleeding (OR 0.97; 95% CI 0.84, 1.11; P = .65; I2 = 56%), and intracranial bleeding (OR 1.14; 95% CI 1.00, 1.30; P = .05; I2 = 32%) were also found between the two groups. No significant differences in stroke or systemic embolism were found between the two groups (OR 0.86; 95% CI 0.74, 1.00; P = .05; I2 = 34%).Conclusion and RelevanceThe concomitant therapy of amiodarone and DOACs did not significantly increase the bleeding risks or decrease the risk of stroke or systemic embolism compared to the DOAC monotherapy. The drug-drug interactions between amiodarone and DOACs may not be clinically significant.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251351148"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Curcumin on miR-21/Tregs and IL-6 in PBMCs From Patients With Myocardial Infarction. 姜黄素对心肌梗死患者外周血中miR-21/Tregs和IL-6的影响

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-07-06 DOI: 10.1177/10742484251351124

Chunmei Tang, Weiwei Lin, Xiaofen Shao, Xiaohu Guo

{"title":"Effects of Curcumin on miR-21/Tregs and IL-6 in PBMCs From Patients With Myocardial Infarction.","authors":"Chunmei Tang, Weiwei Lin, Xiaofen Shao, Xiaohu Guo","doi":"10.1177/10742484251351124","DOIUrl":"10.1177/10742484251351124","url":null,"abstract":"The present study aimed to evaluate the effects of curcumin on the percentage of Tregs as well as miR-21 gene expression and IL-6 levels in peripheral blood mononuclear cells (PBMCs) in patients experiencing myocardial infarction (MI) compared to the controls. Isolation of PBMCs was performed from the peripheral blood of the subjects of the studied groups (50 patients with MI as a case group, and 50 controls). The effects of the low doses of curcumin (0.1 and 1 µM, for 48 h) on the studied parameters were evaluated and compared to the positive and negative controls in vitro. Flow cytometry analysis was used to determine the percentages of regulatory T cells. For gene expression measurement and cytokines assay, Real-time PCR and ELISA were carried out. The proportion of regulatory T cells was markedly lower in PBMCs from patients with MI (P = .03) compared to the controls. microRNA (miR)-21 expression (P = .01) was decreased while the serum level of IL-6 was increased (P = .008) in PBMCs from patients with MI compared to the controls. In vitro, curcumin treatment improved the percentage of Tregs (P =.02) while decreasing miR-21 expression (0.03) and the IL-6 level (P = .02) in PBMCs isolated from patients with MI when compared to untreated cells. The present study provided new insights into the mechanism of the anti-inflammatory effect of curcumin by affecting miR-21/Tregs in MI. Therefore, curcumin may be effective in the improvement of cardiac injury after MI through immunomodulatory mechanisms.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251351124"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Administration of β-Nicotinamide Mononucleotide Attenuates Myocardial Dysfunction in Tail-Suspended Mice. β-烟酰胺单核苷酸可减轻尾悬小鼠心肌功能障碍。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-08-17 DOI: 10.1177/10742484251369609

Wenyu Gu, Dan Liu, Lei Wei, Ziying Yang, Shumin Jiang, Shiyu Dai, Ting Cao, Zhenya Shen

{"title":"Administration of β-Nicotinamide Mononucleotide Attenuates Myocardial Dysfunction in Tail-Suspended Mice.","authors":"Wenyu Gu, Dan Liu, Lei Wei, Ziying Yang, Shumin Jiang, Shiyu Dai, Ting Cao, Zhenya Shen","doi":"10.1177/10742484251369609","DOIUrl":"10.1177/10742484251369609","url":null,"abstract":"Microgravity conditions cause myocardial atrophy and dysfunction with limited therapeutics. Accumulating evidence demonstrates that the deficiency of nicotinamide adenine dinucleotide (NAD+) contributes to myocardial dysfunction under microgravity, making NAD+ boosting an appealing therapeutic approach. In this study, we sought to investigate whether β-nicotinamide mononucleotide (NMN), a precursor of NAD+, preserved cardiomyocytes size and myocardial function during microgravity. Simulated microgravity was induced by tail-suspension in C57BL/6 mice for 28 days. NMN (100 mg/kg body weight) was given every other day after the onset of tail-suspension. Tail-suspension reduced the NAD+ content in hearts and decreased the heart weight and cardiomyocytes size, and cardiac function. Administration of NMN attenuates myocardial atrophy and preserves myocardial function in tail-suspended mice. These cardioprotective effects of NAD+ repletion were associated with the reduction of oxidative stress and improvement of autophagic flux. These findings indicate that NMN may hold great potential as a therapeutic approach for myocardial abnormalities under microgravity conditions.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251369609"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Evaluation of QTc Interval Prolongation With the Dual Endothelin Receptor Antagonist Aprocitentan. 双内皮素受体拮抗剂阿普昔坦对QTc间期延长的临床评价。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-09-12 DOI: 10.1177/10742484251351135

P N Sidharta, J M Brussee, A Schultz, J Wierdak, J Dingemanse

{"title":"Clinical Evaluation of QTc Interval Prolongation With the Dual Endothelin Receptor Antagonist Aprocitentan.","authors":"P N Sidharta, J M Brussee, A Schultz, J Wierdak, J Dingemanse","doi":"10.1177/10742484251351135","DOIUrl":"10.1177/10742484251351135","url":null,"abstract":"IntroductionAprocitentan, is an orally active, once-daily administered, dual endothelin receptor antagonist that was recently approved for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.MethodsThe potential of aprocitentan to affect the QT interval was investigated in this thorough QT/QTc study that was performed as a multiple-dose, randomized, double-blind, placebo- and moxifloxacin-controlled (open-label), crossover study in healthy male and female subjects. Concentration-QT modeling, using a linear mixed-effects model, was performed on data extracted from continuous Holter electrocardiogram recordings.ResultsOf the 48 subjects enrolled in the study, 32 subjects completed study treatment. The main reasons for stopping study treatment were the occurrence of adverse events and withdrawal of consent. The dosing regimen of 25 mg aprocitentan o.d. (the highest approved therapeutic dose in the European Union; Cmax = 3.68 µg/mL) was safe and well tolerated; the supratherapeutic dosing regimen of 100 mg aprocitentan o.d. showed limited tolerability. Results indicated that ΔΔQTcF increased with increasing aprocitentan concentrations. The predicted upper bound of the 2-sided 90% ΔΔQTcF confidence interval exceeded the 10 ms threshold of regulatory concern at 16.10 µg/mL, which was close to the geometric mean maximum concentration (ie, 16.77 µg/mL) obtained with a 100 mg supratherapeutic dose.ConclusionsAt the highest therapeutic dose of 25 mg, there was no clinically significant prolongation of QTc. The risk of QT prolongation with therapeutic doses of aprocitentan is considered low.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251351135"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction: Pioglitazone Attenuates Cardiac Fibrosis and Hypertrophy in a Rat Model of Diabetic Nephropathy. 撤回：吡格列酮减轻糖尿病肾病大鼠模型的心肌纤维化和肥厚。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-10-09 DOI: 10.1177/10742484251381292

引用次数: 0

Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment. 阿托伐他汀和PCSK9抑制剂在临界冠状动脉病变患者中的临床疗效：血管内超声评估。

IF 2.8 4区医学

Journal of Cardiovascular Pharmacology and Therapeutics Pub Date : 2025-01-01 Epub Date: 2025-07-23 DOI: 10.1177/10742484251361059

Zeyu Xu, Yi Fang, Yong Peng, Chunhua Zhang, Chunhua Zheng

{"title":"Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment.","authors":"Zeyu Xu, Yi Fang, Yong Peng, Chunhua Zhang, Chunhua Zheng","doi":"10.1177/10742484251361059","DOIUrl":"10.1177/10742484251361059","url":null,"abstract":"BackgroundWhile PCSK9 inhibition has proven safe and effective, there is limited research on using intravascular ultrasound (IVUS) to assess the impact of atorvastatin combined with PCSK9 inhibitors on borderline coronary lesions.MethodsFrom June 2022 to June 2025, a detailed analysis of biochemical markers, coronary angiography (CAG), and IVUS was conducted on 69 patients with borderline coronary lesions after different treatments.ResultsOf the 69 patients enrolled, 60 completed the 48-week study. All groups showed significant low-density lipoprotein cholesterol (LDL-C) reductions, with Group C (Alirocumab + Atorvastatin) having the largest decrease from 3.64 to 1.48 (P < .001). At 48 weeks, arterial lumen volumes increased in all groups, but Group C's was significantly larger than Groups A (Alirocumab + placebo) and B (Atorvastatin + placebo) (P = .038). Group C also had a greater reduction in plaque volume compared to Groups A and B (P = .041).ConclusionAlirocumab and Atorvastatin together significantly lowered LDL-C levels and improved the vascular environment, notably reversing plaque in patients with borderline coronary lesions.","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"30 ","pages":"10742484251361059"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0